Table 2.
Plasma amino acid concentrations at baseline and after intervention by randomization group
| ω-3 (n=11) | Placebo (n=9) | P Value | ||
|---|---|---|---|---|
| Branched chain AA (μmol/L) | ||||
| Baseline | 225 (195–275) | 248 (233–280) | 0.28 | |
| 12 weeks | 225 (209–296) | 283 (263–301) | 0.14 | |
| δ | 16 (−6–41) | 29 (−2–78) | 0.58 | |
| Essential AA (μmol/L) | ||||
| Baseline | 646 (552–777) | 649 (624–690) | 0.74 | |
| 12 weeks | 648 (609–746) | 691 (668–793) | 0.25 | |
| δ | 46 (−108–132) | 75 (−9–158) | 0.40 | |
| Nonessential AA (μmol/L) | ||||
| Baseline | 1047 (885–1330) | 786 (721–955) | 0.17 | |
| 12 weeks | 1305 (975–1325) | 1003 (842–1035) | 0.44 | |
| δ | 155 (−19–334) | 67 (51–286) | 0.85 | |
| Total AA (μmol/L) | ||||
| Baseline | 1693 (1573–2058) | 1441 (1360–1628) | 0.19 | |
| 12 weeks | 1901 (1710–2095) | 1748 (1533–1851) | 0.32 | |
| δ | 80 (−85–587) | 131 (42–545) | 0.80 | |
Data are presented as median with interquartile range. Unadjusted P value was estimated with Wilcoxon rank sum test. AA, amino acids; δ, difference from baseline to 12 weeks.